LIGAND PHARMACEUTICALS INCORPORATED Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$7.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-02-27
- LIGAND PHARMACEUTICALS INCORPORATED valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2015-12-31 was -$204.22M.
- LIGAND PHARMACEUTICALS INCORPORATED valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$7.30M.
- LIGAND PHARMACEUTICALS INCORPORATED valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$1.60M.
- LIGAND PHARMACEUTICALS INCORPORATED valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was -$1.20M, a 104.84% decline from fiscal 2022.
- LIGAND PHARMACEUTICALS INCORPORATED valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $24.80M, a 121.43% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | -$7.30M 10-K · filed 2026-02-27 | |||
| 2024-12-31 | -$1.60M 10-K · filed 2026-02-27 | |||
| 2023-12-31 | -$1.20M 10-K · filed 2026-02-27 | $1.20M 10-K · filed 2024-02-29 | ||
| 2022-12-31 | $24.80M 10-K · filed 2024-02-29 | $21.50M 10-K · filed 2023-02-28 | ||
| 2021-12-31 | $11.20M 10-K · filed 2024-02-29 | $11.40M 10-K · filed 2022-02-28 | ||
| 2020-12-31 | -$116.50M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $136.90M 10-K · filed 2022-02-28 | -$136.90M 10-K · filed 2020-02-27 | ||
| 2018-12-31 | -$2.50M 10-K · filed 2021-02-24 | |||
| 2017-12-31 | $8.40M 10-K · filed 2020-02-27 | -$8.40M 10-K · filed 2018-03-01 | ||
| 2016-12-31 | $6.30M 10-K · filed 2019-02-28 | |||
| 2015-12-31 | -$204.22M derived: 10-K 12 month − 10-K 9 month · filed 2018-03-01 | -$231.70M 10-K · filed 2018-03-01 | -$230.70M 10-K · filed 2016-02-26 | |
| 2015-09-30 | -$27.48M 10-K · filed 2016-11-14 | |||
| 2014-12-31 | -$7.20M 10-K · filed 2017-02-28 | -$5.40M 10-K · filed 2014-12-01 | ||
| 2013-12-31 | -$5.40M 10-K · filed 2016-11-14 | |||
| 2012-12-31 | $41.80M 10-K · filed 2015-02-23 | |||
| 2011-12-31 | -$15.40M 10-K/A · filed 2014-12-12 | |||
| 2010-12-31 | $30.60M 10-K · filed 2013-03-14 |